NEWM&A

Neurocrine (NBIX) $2.5B Deal for Soleno Therapeutics

Published on 4/6/2026

#NBIX#M&A#biotech
Neurocrine (NBIX) $2.5B Deal for Soleno Therapeutics

AI Summary

Neurocrine Biosciences (NBIX) is nearing a deal exceeding $2.5 billion to acquire Soleno Therapeutics. Soleno Therapeutics has developed the first commercialized drug aimed at treating extreme hunger associated with Prader-Willi syndrome. This acquisition could enhance Neurocrine's product portfolio and expand its market capabilities in the biotech sector. The transaction highlights ongoing consolidation within the pharmaceutical industry, particularly focused on innovative treatments for rare diseases.

Source: Read original article (opens in new tab)

Related News

Danantara (DANA) Advances Asset Manager Merger with $159 Million Deal
M&A

Danantara (DANA) Advances Asset Manager Merger with $159 Million Deal

Apr 6

UPS (UPS) Teamsters Settlement Caps Driver Severance Offers
M&A

UPS (UPS) Teamsters Settlement Caps Driver Severance Offers

Apr 6

Paramount (PARA) secures $24 billion for Warner deal funding
M&A

Paramount (PARA) secures $24 billion for Warner deal funding

Apr 5

Paramount (PARA) $81 Billion Warner Acquisition Supported by Gulf Funds
M&A

Paramount (PARA) $81 Billion Warner Acquisition Supported by Gulf Funds

Apr 5